Citius Oncology, Inc. (CTOR)
Healthcare
Drug Manufacturers - Specialty & Generic
0.63 $
+5.6%
vs. previous close
Closing price · As of: 3. Aug 2026
Citius Oncology, Inc. (CTOR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -5.5 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0.0 | -0.6 | 0.1 | -5.5 | |
| 0.0 | 2.0 | 7.5 | 8.3 | |
| 0.1 | 0.4 | 13 | 9.9 | |
| 0.0 | 0.0 | 0.0 | 0.0 | |
| -67 | -1.3 | -5.0 | -5.8 | |
| – | 0.0 | 3.8 | 0.0 | |
| 68 | 1.7 | 4.9 | 15 | |
| 0.3 | -0.3 | 0.0 | 3.9 | |
| 0.0 | -0.6 | 0.1 | -5.5 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.